⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

February 3, 2023Blood AdvancesOpen Access

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS

Anna Stengel Torsten Haferlach Constance Baer Stephan Hütter Manja Meggendorfer Wolfgang Kern Claudia Haferlach

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to investigate how specific TP53 events affect prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Examined subtype distribution of single-hit and double-hit TP53 events
Analyzed survival outcomes in a cohort of patients with AML and MDS
Utilized statistical methods for assessing prognosis based on TP53 alterations.
Patients with double-hit TP53 events had a significantly worse prognosis compared to those with single-hit events (HR: 2.5, 95% CI: 1.5-4.0, p<0.01)
Certain subtypes showed distinct survival outcomes, indicating specific prognostic value
Overall findings suggest that TP53 event type should be considered in treatment planning.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Explores prognosis based on TP53 events in AML and MDS, suggesting implications for treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stengel et al. (2023) studied this question.

synapsesocial.com/papers/6a0857ee9a6c4ba6e610937c https://doi.org/10.1182/bloodadvances.2022009100

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Prognostic impact of ‘multi-hit’ <i>versus</i> ‘single hit’ <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases2024 · 13 citations
2TP53-mutated Acute Myeloid Leukemia through a single-cell lens2025
3TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy2025 · 1 citations
4Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type2025 · 6 citations
5<i>TP53</i> variant allele frequency as a driver of survival in <i>TP53</i> -mutated acute myeloid leukemia.Cohort Study · 2026
6Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
7Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantationOriginal Research · 2026
8Therapy-related myeloid neoplasms with single-hit <i>TP53</i> mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts2024 · 1 citations
9Idiopathic Multicentric Castleman Disease Unresponsive to One IL-6 Inhibitor May Respond to Another IL-6 InhibitorBlood Advances · 2026
10Active Surveillance of JAK2V617F Clonal Hematopoiesis Toward Myeloproliferative NeoplasmsBlood Advances · 2026

More from Blood Advances

More from Munich Leukemia Laboratory (Germany)